Immunization has played an integral role in
improving children’s health and survival in India. The Ministry of Health and Family Welfare has been
consistently working towards reducing the mortality rates from
vaccine-preventable diseases through its Universal Immunization Programme
(UIP). Immunization doesn’t just save
medical costs, but also yields indirect economic benefits like educational
attainment, enhanced productivity. The unimmunized individuals are also offered
protection through “herd immunity” by many vaccines.
India has made significant progress towards reducing child deaths and has set multiple child health targets to achieve. The government of India has taken multiple steps to accelerate child survival, including strengthening the routine immunization (RI) programme of the country. Since 1990, the child mortality rates of the country have declined by 58%. So far, Vaccines have successfully eradicated smallpox and polio from the country. Measles have brought to an all- time low and tetanus has been reduced to a large extent. As of 2013, 18 states were estimated to have eliminated maternal and neonatal tetanus. Over the years, India has seen progress in expanding immunization coverage, with nationwide coverage of the third dose of the diphtheria-tetanus-pertussis (DTP) vaccine increasing to an estimated 72% in 2012 from 60% in 2003.
The industry stands on remarkable success
that exemplifies “Make in India” while the road ahead calls for strategic
maneuvering and funding. The global foothold is consistently strengthened which
is crucial to remain successful, however, the need of the hour is to evaluate
the evolving domestic market
landscape.
Vaccines
have transformed public health throughout the world, for children particularly,
the burden of vaccine-preventable diseases in India is still substantial and
hence the usage of this powerful tool is still not optimal in our country. The
Indian healthcare industry presents new vistas of growth, provided, challenges
in terms of policy barriers, lack of awareness and affordability issues, are
successfully tackled. Some
of the challenges can be explained as -
Technical
Challenges: -
Technology has been a conspicuous obstruction in the case of few
emerging vaccines. Hence, this results in significantly higher product risk, higher
than it has been in all previously developed vaccines.
IP Policies: - We need stringent IP policies and an
ecosystem where research is prized and not just encouraged. Hence, at the end
its not only a question of sustained industry competitiveness, it is a question
of appropriate and active public response to a critical national need.
Regulatory
Challenges: -
Many a times procedural hold-ups delay product development and launch,
which in turn have proven truly expensive – not only to the industry but to the
country as such. While the industry stakeholders have now begun a constructive
dialogue to wash out certain regulatory delays, the magnitude of the problem
calls for a collaborative approach that is as aggressive as it can be.
In a wake to address the
regulatory issues of Indian vaccine industry, Union Health Ministry has
recently announced that it will be forming an expert group to examine
regulatory issues for Indian vaccine industry. "Indian vaccines
manufacturers should accord prime importance to meeting domestic demand,
upscale research and development related work, and also take initiatives in
developing critical vaccines such as Pneumococcal conjugate vaccine (PCV) and
Human Papillomavirus (HPV) vaccines" said Union Health Secretary C K
Mishra. The expert group will work towards speedy resolution of issues in
time-bound manner without compromising critical aspects like quality, patient
safety and patient management.
More of such initiatives and
planned multi-stakeholder approach is required for conquering challenges of
complex emerging vaccines that lie ahead. It is critical that policymakers and
regulators alike, maintain the pace in such efforts and work in full force to
help India win over the next set of public health challenges.
No comments:
Post a Comment